XTL Biopharmaceuticals Ltd. (XTLB) NASDAQ
2.31
-0.095(-3.96%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.31
-0.095(-3.96%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
10
First IPO Date
September 01, 2005
| Name | Title | Pay | Year Born |
| Noam Band | Chief Executive Officer & Director | 0 | 1970 |
| Segal Niv | Chief Financial Officer | 0 | N/A |
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.